Apprentice safeguards $2.5 million for augmented reality tool aimed toward biopharma manufacturing

Jersey City, Nj-based Apprentice is getting augmented reality towards the arena of pharma and biotech manufacturing.

The startup lately elevated $2.5 million to assist it pursue its goal. Charge investor was Silverton Partners, and Hemi Ventures also participated.

Inside a phone interview, Apprentice cofounder and Chief executive officer Angelo Stracquatanio stated the funding may be the company’s seed round.

Advertisement

“We view it like a positive sign the market is relocating the direction we’d always wished it might relocate,” he stated. “AR has been adopted in a commercial scale.”

Stracquatanio noted the money will be used to expand their development area, work on R&D and improve its core product.

Apprentice’s solution has three primary modules, which operate on smart glasses like Google Glass and Microsoft HoloLens.

The very first, known as Tandem, is aimed toward collaboration. When an worker needs the help of an issue expert, Tandem enables the happy couple to speak, even if they’re in various locations. While using tool, the remote expert can easily see exactly what the worker around the manufacturing floor sees and coach her or him with the issue.

Another area of the solution, Manuals, can serve as the startup’s process and workflow aid. It enables users to possess hands-free use of operating procedures along with other tasks.

Gauge may be the third bit of the puzzle and is dependant on data collection and safety at work. Instead of spending exorbitant intervals recording information, operators may use the module to collect lab and manufacturing data while performing another task.

The best goal would be to leverage augmented reality to enhance efficiency and safety in laboratory and manufacturing environments.

“We were so inspired by Apprentice’s desire for using the most advanced technology to provide real solutions for labs and sophisticated manufacturers,” Mike Dodd, partner at Silverton Partners, stated inside a statement. “They are management in making use of augmented reality to supply direct client benefits because of the users’ enhanced operational experience.”

Stracquatanio stated Apprentice’s revenue model has two phases.

The very first is an airplane pilot phase, where the organization provides from the program towards the smart glasses to some client. The Jersey City startup also provides the customer with training and support through the duration of the pilot, which generally lasts between one and three several weeks.

“If you place it and end up forgetting it, it is not fruitful on their behalf or us,” Stracquatanio stated. “We address it like a collaborative effort.”

Following the early on, Apprentice relies on a software-as-a-service model with different per device or per user basis.

Photo: abluecup, Getty Images

Vehicle T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma

ATLANTA, 12 ,. 10, 2017 /PRNewswire-USNewswire/ — For individuals with certain kinds of aggressive, refractory bloodstream cancers, treatments are woefully limited. But three studies being presented today in the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight the emerging role performed by chimeric antigen receptor (Vehicle) T-cell therapies in assisting individuals mount a clinical response and, in some instances, achieve durable remission.

These therapies are made by harvesting an individual’s own T-cells (the immune system’s primary cancer-killing cells), reengineering these to target specific proteins at first glance of leukemia and lymphoma cells, and reintroducing the modified T-cells into the patient’s defense mechanisms.

“It’s encouraging the data continue being so strong and claim that Vehicle-T therapies for B-cell malignancies are not going anywhere soon,” stated press briefing moderator, Renier J. Brentjens, MD, PhD, medical oncologist and director of cellular therapeutics at Memorial Sloan Kettering Cancer Center. “There’s still a great deal we have to find out about toxicities — for instance, how you can manage cytokine release syndrome (CRS), a typical, potentially harmful response to this kind of infusion.”

In 2 separate, longer-term follow-up analyses (from the ZUMA-1 and JULIET trials), researchers discovered that initial responses were sustained with time in patients who received genetically modified T cells made to concentrate on the CD-19 protein, that is frequently expressed on malignant lymphoma cells. Another, Phase I study — among the largest to judge a Vehicle therapy targeting BCMA, a marker present on most multiple myeloma tumor cells — demonstrated encouraging early leads to patients with heavily pre-treated multiple myeloma.

“This is an exciting time. According to these results and up to date Food and drug administration approvals in this subject, there’s need to be reassured that cell therapies, for example Vehicle-T, may eventually be the grade of take care of hematologic malignancies in addition to solid tumors,” stated Dr. Brentjens.

This press conference will occur on Sunday, December 10, at 10:30 a.m. EST in Room A315 from the Georgia World Congress Center.

Responses to Vehicle T-Cell Therapy Still Strong after Twelve Months in Patients with Refractory National hockey league, Data also Reveal Why Therapy Fails in certain Patients

Lengthy-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (National hockey league) [578]

Among 108 patients with fast-growing and refractory aggressive non-Hodgkin lymphoma (National hockey league), over fifty percent remained as alive more than a year after getting a single infusion of the Vehicle T-cell therapy, axicabtagene ciloleucel (axi-cel), that targets the CD-19 protein frequently available on cancerous lymphoma cells, researchers reported. This latest analysis of ZUMA-1, which mixes Phase I and II trial data, assessed the speed and sturdiness of responses and survival of these patients following a median follow-from 15.4 several weeks. Several year following a single infusion of axi-cel, 42 percent of patients stay in remission and 40 % of patients exhibit no proof of cancer.

“Lengthy-term follow-from ZUMA-1 confirms these responses could be durable and also the ongoing responses at 24 several weeks claim that late relapses are uncommon. Patients who’re in remission at 6 several weeks tend in which to stay remission,” stated lead study author Sattva S. Neelapu, MD, professor in the College of Texas MD Anderson Cancer Center. “With existing therapy, the median survival for those who have this ailment is just 6 several weeks. Here, we have seen over fifty percent of patients — 59 percent — continue to be alive more than a year after treatment.”

The research, which is happening at 22 sites, may be the largest study of the Vehicle T-cell therapy’s effectiveness up to now, based on researchers. Dr. Neelapu explains the durability findings will also be in line with observations from earlier, single-institution trials of axi-cel within this patient population. When it comes to safety, no new deaths associated with the treatment happened. At the start of the research, four patients died within two several weeks of treatment — two due to the Vehicle T-cell therapy and yet another two to unrelated adverse negative effects which are usual for disease progression. Within the pivotal part of ZUMA-1, common adverse occasions contained CRS, neurologic toxicities, neutropenia, anemia, and thrombocytopenia. Ten patients possessed a serious adverse event six several weeks following the primary analysis, including infections in eight patients. No new onset CRS or neurologic occasions associated with axi-cel were noticed in the updated analysis.

The research offers a few of the first clues why some patients relapse or don’t react to Vehicle T-cell therapy After analyzing tumor tissue from pre and post treatment in patients who relapsed, they discovered that inside a third of patients the CD19 protein wasn’t any longer present on cancer cells. Next, greater than two-thirds of tumors demonstrated proof of another protein, PD-L1, likely helping the cells of cancer survive by inhibiting the part from the infused T cells. Follow-up research is now going ahead to recognize possible methods to overcoming these complaints.

You will find roughly 72,000 new installments of National hockey league within the U.S. every year. National hockey league starts in white-colored bloodstream cells known as lymphocytes, which are members of the defense mechanisms. There’s two primary kinds of lymphocytes — B-cells and T-cells — whose role would be to assist the body fight infection.

A randomized trial to check the effectiveness of the therapy with second-line standard of care, including autologous stem cell transplantation for relapse after first-line therapy, is planned in patients with aggressive B-cell National hockey league.

Funding with this study was supplied by Kite Pharma, Corporation., now Gilead Sciences.

Sattva S. Neelapu, MD, The College of Texas MD Anderson Cancer Center, will show this research throughout an dental presentation on Monday, December 11, at 7:00 a.m. EST in Room A411 from the Georgia World Congress Center.

Six-Month Analysis of Tisagenlecleucel in Persistent Type of Lymphoma Shows Sustained Responses

Primary Analysis of Juliet: A Worldwide Pivotal Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma [577]

Six several weeks after getting a single dose of tisagenlecleucel, a Vehicle T-cell therapy that targets CD-19, high response rates persist among adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based on researchers.

This latest interim research into the worldwide JULIET trial demonstrated that for 46 patients with a minimum of 6 several weeks of follow-up, the general response rate was 37 percent, with 30 % achieving an entire response and seven percent achieving an incomplete response. In addition, based on researchers, this observation signifies that, among 81 patients treated, individuals whose indications of cancer choose to go away at 3 several weeks continued to be relapse-free at 6 several weeks and beyond.

“Basically we don’t understand fully the remissions are extremely durable, it’s exciting and can change how this ailment is treated when conventional therapies fail,” stated lead study author Stephen Schuster, MD, Professor of Hematology/Oncology within the Perelman Med school in the College of Pennsylvania (Penn) and Penn’s Abramson Cancer Center. “We will have the ability to offer patients that do not react to standard therapies a kind of therapy that could, following a single treatment, relieve signs and symptoms and save lives.”

DLBCL is easily the most common type of lymphoma, comprising roughly one-third of non-Hodgkin lymphoma cases. While current treatments are effective for most people with this particular disease, individuals not answering current treatments face an undesirable prognosis with limited treatments. Based on Dr. Schuster, primary therapy will fail within one-third of individuals with DLBCL, and 1 / 2 of these patients won’t be candidates for stem cell transplantation, which is the best second-line treatment approach such patients could be candidates for this kind of therapy.

This single-arm, open-label Phase II trial may be the largest study analyzing a Vehicle T-cell therapy solely in individuals with DLBCL. It is happening at 27 sites spanning 10 countries across The United States, Europe, Australia, and Asia. Enrollees had received several lines of prior chemotherapy coupled with disease progression, or had unsuccessful to reply or were ineligible for autologous stem cell transplant. Patients ranged in age from 22 to 76 years of age.

Subgroup analyses demonstrated no improvement in outcomes according to prior DLBCL treatment or risks. From the 81 patients incorporated in JULIET, the responding patients continue being adopted with no additional therapy, and median durable overall response and overall survival haven’t yet been arrived at.

The majority of the adverse occasions were seen soon after infusion and incorporated CRS and neurotoxicities. There have been no deaths due to CTL019, CRS, or nerve occasions.

Dr. Schuster stated several factors set this trial aside from other investigations of Vehicle T-cell therapies, including the therapy ended with an outpatient grounds for many patients (26 %) and also the manufacturing process permitted investigators to create Vehicle T cells from formerly collected and frozen bloodstream cells, permitting effective shipment all over the world.

“When the Vehicle T cells were generated, we’re able to freeze them again, allowing us to carry the merchandise until patients were clinically prepared to receive them,” he stated. “They are very sick patients, which means this provides the treating physician some versatility to schedule therapy when it is perfect for each patient.”

Patients within the JULIET trial who taken care of immediately therapy continue being adopted carefully for recurrence of the lymphoma and recovery of the defense mechanisms.

Funding with this study was supplied by Novartis. 

Stephen J. Schuster, MD, College of Pennsylvania, will present this research throughout an dental presentation on Monday, December 11, at 7:00 a.m. EST in Room A411 from the Georgia World Congress Center.

Clinical Activity Seen with Anti-BCMA Vehicle T-Cell Therapy in Phase 1 Study of individuals with Heavily Pre-Treated Multiple Myeloma

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Is a result of a Multicenter Study of bb2121 Anti-BCMA Vehicle-T Cell Therapy [740]

A 1-time infusion of the investigational Vehicle T-cell therapy that targets a protein available on most multiple myeloma cells elicited an 86-percent overall response rate in 21 patients whose disease had return or hadn’t responded following a median of seven prior treatments, based on is a result of a Phase I study.

Among 18 patients who received greater, active doses of infused Vehicle T cells, this response rate elevated to 94 percent, with manageable negative effects, researchers reported. Of these 18 patients, 10 achieved an entire response and 9 of 10 evaluated for minimal residual disease (MRD) using sensitive genetic tests achieved an MRD-negative response. Following a median follow-up duration of 40 days, the median progression-free survival was not arrived at four patients who received active doses saw their disease worsen.

“We’re looking forward to the first produces a patient population with very advanced myeloma to whom previous therapies have unsuccessful,” stated senior study author James N. Kochenderfer, MD, from the Center for Cancer Research in the National Cancer Institute in Bethesda, Maryland.

These bits of information are essential, Dr. Kochenderfer stated, because despite recent therapeutic advances, multiple myeloma — a cancer that begins in plasma cells, cells within the bone marrow that assist the body fight infection — remains nearly incurable. Existing therapies require patients to remain on treatment lengthy-term with drugs which have negative effects, he stated.

“Vehicle T-cell treatments are totally different from other available treating multiple myeloma,” Dr. Kochenderfer stated. “We’ve patients who’ve a sustained response and also have had the ability to choose more than a year without any additional myeloma therapy and tolerable negative effects.”

The research, conducted at nine sites in the U . s . States, may be the first U.S.-based multicenter study of the Vehicle T-cell therapy engineered to focus on BCMA, a protein available on most both myeloma tumor cells and normal plasma cells, but not one other healthy tissues. An believed 30,000 individuals the U . s . States is going to be identified as having multiple myeloma in 2017.

Twenty-one patients having a median chronilogical age of 58 years were signed up for the dose-escalation phase from the study. Had seen their disease return or stop responding following a median of seven prior treatments, together with a stem cell transplant.

The main purpose of the Phase I study ended up being to find out the “maximum tolerated dose” from the experimental treatment — that’s, the greatest dose that may be given without unacceptable amounts of negative effects. Additional outcome measures incorporated evaluating whether any cancer cells continued to be within the bone marrow, the amount of time before the cancer started to obtain worse, and reaction to treatment as measured with a standard group of criteria for assessing multiple myeloma.

Most sufferers experienced negative effects, including low bloodstream counts, CRS, and neurologic signs and symptoms. The 3 patients treated in an inactive Vehicle-T dose, the cheapest dose within the dose-escalation stage from the trial, died from advancement of their myeloma within twelve months. One of the 18 patients treated at active Vehicle-T doses, two patients died using their company causes while their myeloma is at an entire reaction to Vehicle-T therapy.

These bits of information are preliminary and, like a Phase I trial, the research didn’t have control group and it was designed mainly to recognize a secure dose of bb2121, to not assess the drug’s effectiveness.

Funding with this multi-site study was supplied by Celgene Corporation and bluebird bio, Corporation.

James N. Kochenderfer, MD,of National Cancer Institute, will show this research throughout an dental presentation this research on Monday, December 11, at 2:45 p.m. EST in Hall C1 from the Georgia World Congress Center.

The research authors and press program moderator is going to be readily available for interviews following the press conference or on the phone. Additional press briefings will occur through the meeting. For that complete annual meeting program and abstracts, visit world wide web.hematology.org/annual-meeting. Follow @ASH_hematology and #ASH17 on Twitter and like ASH on Facebook which are more up-to-date details about the 2017 ASH Annual Meeting.

The American Society of Hematology (ASH) (world wide web.hematology.org) may be the world’s largest professional society of hematologists focused on furthering the understanding, diagnosis, treatment, and protection against disorders affecting the bloodstream. In excess of half a century, the Society has brought the introduction of hematology like a discipline your clients’ needs research, patient care, education, training, and advocacy in hematology. The Society publishes Blood® (world wide web.bloodjournal.org), probably the most reported peer-reviewed publication within the field, along with the online, open-access journal, Bloodstream Advances® (world wide web.bloodadvances.org).

Cision View original content:http://world wide web.prnewswire.com/news-releases/vehicle-t-cell-therapies-drive-outcomes-in-lymphoma-myeloma-300569372.html

SOURCE American Society of Hematology

Related Links

http://world wide web.hematology.org

Which pharma information mill probably the most transparent with medical trial data?

New research co-created by the founding father of Bioethics Worldwide, a non-profit focused on ethics and transparency within the pharmaceutical sector, determined that Manley and Manley and Sanofi/Genzyme earned top marks and were far above other drug developers at discussing medical trial data. The research was printed in BMJ Open —an online, open access journal, which publishes scientific research all disciplines and therapeutic areas.

The research centered on the 19 drugs approved in 2014, so pharma companies that didn’t get drugs approved that year, Pfizer and GlaxoSmithKline, weren’t incorporated within the Good Pharma Scorecard.

The research found that the median proportion of trials conducted in patients with openly available results rose from 87 percent this year once the first such study ended to 96 percent in 2014.

Advertisement

Other notable findings were that 10 of 19 drugs (53 %) had a minumum of one undisclosed trial conducted in patients. Six drugs (32 percent) had a minumum of one undisclosed phase II or III trial. A minimum of 2,864 patients took part in trials with undisclosed results.

Jennifer Miller, a bioethicist at New You are able to College and founding father of Bioethics Worldwide stated the following edition of clinical data discussing league tables includes patient-level data discussing — data which scientific organizations have pressed for inclusion, based on the Researcher. It’ll also explore reporting transparency for trials connected with unapproved drugs that have been only lately needed to become reported underneath the FDAAA.

A table in the study printed in BMJ Open:

Companies’ overall medical trial transparency rankings for drugs approved in 2014*

Rank Company Transparency score (%)
#1 Manley & Manley/Janssen 100
#1 Sanofi/Genzyme 100
#3 Abbvie 96
#4 Celgene 95
#5 Merck 93
#6 AstraZeneca 91
#7 Roche 90
#8 Novartis 88
#9 Gilead 73
#10 Allergan 63
#11 Valeant 50
Median 91

Photo: Natali_Mis, Getty Images

Roche’s cancer of the lung data look great, why didn’t the marketplace respond to medical trial results?

Basel, Europe-based Roche has announced great news, by having an update on its  IMpower150 trial. The information reveal that adding its anti-PD-L1 drug Tecentriq (atezolizumab) to a set of older drugs reduced the chance of disease worsening or dying by 38 percent for patients with advanced non-squamous non-small cell cancer of the lung (NSCLC).

Roche notes that this is actually the very first time a mixture immunotherapy trial has effectively elevated progression-free survival (PFS) within this population, according to company news release. Roughly 18 percent of patients given a mix of Avastin and chemotherapy were progression-free in the 12-month mark — time greater than bending to 37 percent when Tecentriq was put into this mixture.

Why then, were investors so unimpressed? By late mid-day, Roche’s stock was really lower 2.five percent.

Advertisement

The pessimism is definitely not really a reflection from the market need. Lung cancer may be the second most typical type of cancer in both women and men, based on the American Cancer Society (ACS). More to the point, it is definitely the key reason for cancer dying. Around one in 4 cancer deaths within the U.S. are related to cancer of the lung also it takes more lives than colon, breast, and prostate cancers combined.

With your an excellent market chance, Roche’s challenge might be competition.

A sensational 164 agents targeting PD-1/L1 are presently in development, a brand new report through the Cancer Research Institute (CRI) states. Of individuals, 50 are presently in clinical stage development, five are Food and drug administration-approved, and 4 are apparently vying for that IMpower150 population.

Merck’s Keytruda, Bristol-Myers Squibb’s Opdivo, and AstraZeneca’s Imfinzi are jostling with Tecentriq for any prime position. And it is no easy race to, analysts at Air Vantage noted on Thursday.

For investors, Roche leaves some major questions unanswered.

“The IMpower150 study had three arms: Tecentriq plus chemotherapy (arm A) Tecentriq plus Avastin plus chemotherapy (arm B) and Avastin plus chemotherapy (arm C). To date, complete data are just available evaluating arm B with arm C – and therefore there’s only preliminary information yet about how Tecentriq effectively stacks facing Avastin,” Air Vantage analysts mentioned.

Quite simply, is Avastin really doing the heavy-lifting?

In lots of ways, that summarizes the present condition from the immunotherapy field. With each and every dataset, new questions are unearthed. New patient subsets are thought. Individuals 50 anti-PD1/L1 agents within the clinic have finally boosted 1,502 studies, which 1,105 are combination trials.

A number of these trials are small , operate around just one trial site or center, stated Aiman Shalabi, CRI’s chief medical officer and director from the Anna-Maria Kellen Clinical Accelerator. That presents challenging for investors and perhaps the individual community, as companies pursue overlapping products and analyses.

“Innovation resides in academic centers, and CRI strongly encourages more research and numerous studies according to strong science and new targets to succeed the area,Inches Shalabi authored within an email forwarded with a CRI representative. “However, you will find inefficiencies and duplication identified within the IO landscape analysis, like the crowded PD-1/L1 studies.”

Shalabi props up studies, but believes they must be done “more efficiently and collaboratively via multi-center collaboration and using innovative study designs for example basket and umbrella platforms to judge new combinations and enhance efficiencies over the landscape.”

Meanwhile, details about these key drugs gradually drips from many small studies that can’t easily be compared. That may assistance to explain why Roche’s data didn’t jolt the markets today.

Photo: goir, Getty Images

Sunovion will get Food and drug administration approval for Lonhala Magnair inhalation means to fix treat Chronic obstructive pulmonary disease

Printed 06 December 2017

Sunovion Pharmaceuticals announced the US Fda (Food and drug administration) has approved the brand new drug application (NDA) for Lonhala Magnair (glycopyrrolate) inhalation solution (25 mcg two times daily), also referred to as SUN-101/eFlow, for that lengthy-term, maintenance management of air flow obstruction in individuals with chronic obstructive lung disease (Chronic obstructive pulmonary disease), including chronic bronchitis and/or emphysema.

Sunovion expects LONHALA MAGNAIR to be shown in U.S. pharmacies at the begining of 2018.

LONHALA MAGNAIR may be the first nebulized lengthy-acting muscarinic antagonist (LAMA) approved to treat Chronic obstructive pulmonary disease within the U.S. and also the first utilisation of the MAGNAIR, which is dependant on the closed eFlow technology system, produced by PARI Pharma GmbH, to deal with Chronic obstructive pulmonary disease.

Fraxel treatments is really a virtually silent, portable, closed system nebulizer that is made to provide the drug in 2 to 3 minutes and enables individuals to breathe normally when using the device.

“We are proud the Food and drug administration has approved LONHALA MAGNAIR because the first nebulized, lengthy-acting muscarinic antagonist treatment choice for individuals the U.S. coping with Chronic obstructive pulmonary disease,” stated David Frawley, Executive V . P . and Chief Commercial Officer at Sunovion.

“The approval of LONHALA MAGNAIR underscores our leadership in nebulization and also the value we put on supplying innovative treatments for individuals coping with Chronic obstructive pulmonary disease. LONHALA MAGNAIR is a vital accessory for our portfolio of approved Chronic obstructive pulmonary disease therapies for individuals at various stages of Chronic obstructive pulmonary disease, supplying the versatility to select handheld or nebulized products according to individual needs.”

“Despite the supply of countless therapies, lots of people still find it difficult to control their Chronic obstructive pulmonary disease – challenging which may be impacted by the delivery method accustomed to administer a medicine,Inches stated Gary Ferguson, M.D., Lung Research Institute of Southeast Michigan, Farmington Hillsides, Michigan.

“LONHALA MAGNAIR provides an important new option that mixes the effectiveness of the proven medication for Chronic obstructive pulmonary disease using the features of a distinctive handheld nebulizer that enables someone to breathe normally while taking their medication.”

Roughly 15.seven million adults within the U.S. report they’ve been identified as having Chronic obstructive pulmonary disease, a typical, avoidable and treatable ailment that is characterised by persistent respiratory system signs and symptoms and air flow limitation that is a result of airway and/or lung abnormalities usually brought on by significant contact with toxic particles or gases.1,2

The primary risk factor for Chronic obstructive pulmonary disease is cigarette smoking, but other ecological exposures may lead.2 The condition causes it to be hard that people breathe and subsequently may limit remarkable ability to do some routine activities, such as the proper inhalation of medicine.2 This improper medication technique may impact treatment with time and can even lead to an insufficient quantity of the drug reaching the lung area, potentially worsening an individual’s Chronic obstructive pulmonary disease.3,4,5 For those who have moderate-to-very-severe Chronic obstructive pulmonary disease, nebulized treatments offer an alternative choice to inhalers, allowing someone to breathe normally while taking their medicine.

Your application is dependant on data in the numerous studies within the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) program, which incorporated GOLDEN-3 and GOLDEN-4, two Phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter, effectiveness and safety trials evaluating LONHALA MAGNAIR with placebo in grown-ups with moderate-to-very-severe Chronic obstructive pulmonary disease.

At study endpoints, individuals given LONHALA MAGNAIR shown statistically significant and clinically important changes from baseline in trough forced expiratory volume in a single second (FEV1) at Week 12 versus placebo.

Yet another study, GOLDEN-5, would be a Phase 3, 48-week, randomized, open-label, active-controlled, parallel-group, multicenter safety trial made to assess the lengthy-term safety and tolerability of LONHALA MAGNAIR in grown-ups with moderate-to-very-severe Chronic obstructive pulmonary disease and incorporated the active comparator Spiriva® (tiotropium bromide) delivered through the HandiHaler® device.

LONHALA MAGNAIR was generally well-tolerated in studies, most abundant in common negative effects being exacerbations and cough. The general treatment emergent adverse occasions (TEAE) incidences were similar for glycopyrrolate and tiotropium groups over 48 days.

LONHALA MAGNAIR (glycopyrrolate) Inhalation Solution, also referred to as SUN-101/eFlow®, may be the first lengthy-acting muscarinic antagonist (LAMA) bronchodilator delivered through the MAGNAIR, which is dependant on the closed eFlow® technology system, produced by PARI Pharma GmbH.

The MAGNAIR nebulizer is really a virtually silent, portable delivery device that reduces how long needed to provide the drug to 2 to 3 minutes and enables individuals to breathe normally when using the device. LONHALA MAGNAIR qualifies for that lengthy-term, maintenance management of air flow obstruction in individuals with chronic obstructive lung disease (Chronic obstructive pulmonary disease), including chronic bronchitis and/or emphysema.

Source: Company Pr Release

CVS Health’s $69B deal to get Aetna would create new type of integrated care

Give and take concept on black background

CVS Health insurance and Aetna formally announced their acquisition plan after several weeks of speculation. The $69 billion purchase of Aetna by CVS Health can give the insurer use of CVS Health’s network of Minute Clinic and pharmacy locations and nursing professionals.

The offer gives Aetna the opportunity to offer people care nearer to patients’ homes in a greater diversity of settings that could lower care delivery costs. Within the company’s third-quarter earnings call with analysts captured, Aetna Chief executive officer Mark Bertolini spoken about the advantages of getting alternative care settings to hospitals.

” I believe you need to consider it as being keeping people from the medical-industrial complex by providing better services in your home by meeting social determinants of health, which are big motorists of healthcare expenses today, larger than people understand. After which where we’ve the chance to do blood draws, infusion, imaging, discharge planning, are going to individuals nearer to the house or in your home [more] than we all do today.”

The announcement through the two companies noted the combined network would come with CVS Health’s network includes greater than 9,700 pharmacy locations, 1,100 MinuteClinic walk-in clinics, Omnicare’s senior pharmacy solutions, Coram’s infusion services, and most 4,000 CVS Health nursing professionals supplying in-clinic and residential-based care nationwide.

Another feature for that deal would be a declare that the CVS Health insurance and Aetna would with each other perform a better job of treating chronic conditions, based on the news release. Patients with diabetes could receive care between physician visits through getting counseling at CVS Health food stores via telehealth and remote monitoring of bloodstream blood sugar levels.

“These kinds of interventions are stuff that the standard healthcare system might be doing,” CVS Health Chief executive officer Ray Merlo said in news reports release, “but the standard healthcare system lacks the important thing aspects of convenience and coordination which help to interact consumers within their health. That’s exactly what the mixture of CVS Health insurance and Aetna will provide.Inches

When the deal closes within the second quarter because the companies project, Aetna shareholders will own roughly 22 percent from the combined company and CVS Health shareholders will own roughly 78 percent, based on the news release.

One problem is that the judge could block the offer over antitrust concerns since one accomplished it before when Aetna, putting an finish to Aetna’s intends to acquire Humana.

Within the wider plan of products, the brand new deal not just stands to higher position CVS Health for Amazon’s pharma aspirations but in addition helps CVS Health champion a brand new type of integrated health system. However the agreement also raises some key questions, as Axios highlights. Will CVS Health pressure Aetna people to purchase medications within CVS Health’s network of pharmacies? Maybe there is surcharges for implementing out-of-network pharmacies? Or would that logic be relevant to the moment Clinic’s services? Will this deal spur similar ones between retail drugstores and insurance providers?

Photo: crazydiva, Getty Images

Health Wizz leverages blockchain technology to provide patients control of their data

blockchain

Health Wizz is taking advantage of the growing blockchain trend.

The organization lately unveiled its platform, which enables customers to aggregate and share their personal health information.

The Falls Church, Virginia-based startup also took part in the Pitch Perfect contest at MedCity Participate in October.

Advertisement

Inside a recent interview, Chief executive officer Raj Sharma pointed to some couple of key explanations why Health Wizz made the decision to make use of blockchain technology to power the woking platform.

The first is the problem of security. “We as consumers have finished having faith in institutions with this data,” he stated. “For us, it had been really key that even if our consumers use our application, it normally won’t need to trust us. They need to trust blockchain.”

Furthermore, Sharma noted the startup wanted to produce a marketplace of health data where pharmaceutical companies, research organizations yet others can talk to consumers. Blockchain was a good way to create these connections happen and permit groups to liaise even if it normally won’t trust one another.

Health Wizz’s platform works as a result: Patients can observe and download their data from hospitals, their doctor yet others. Furthermore, specific organizations may use cryptocurrency to incentivize patients to lead their own health data for research. This currency comes by means of OmCoin, an electronic Ethereum token from Health Wizz. These tokens function as digital access keys, allowing users to switch information.

North Park-based MintHealth is yet another player on the market is leveraging blockchain similarly. Their lately revealed self-sovereign personal health record utilizes we’ve got the technology. Patients have access to MintHealth online or using a mobile application. Every individual includes a global identifier that enables these to access their information and oversee permissions into it. There’s also payer-funded digital incentive tokens known as vidamints, which patients receive once they take part in healthy behaviors. They may then make use of the tokens to assist purchase healthcare-related costs.

Sharma stated that although Health Wizz and MintHealth both use blockchain, the businesses will vary.

“We are utilizing an open Ethereum blockchain,” he stated. “We don’t really put data around the blockchain itself. We put keys around the blockchain. [The data] ranges from the participant towards the medical trial. It’s a really different approach meaning that … many others are speaking about putting data around the blockchain.”

Searching ahead, Sharma listed three key areas the startup intends to pay attention to.

First, Health Wizz really wants to make its tools simple to use and for that reason appealing to consumers. The 2nd step, which the organization has began, is normalizing the information so others have access to it. Finally, in regards to a year lower the street, the startup is fine with having 4 or 5 pharma or medical trial companies getting together with its consumers.

“If a couple of hundred finish users may take place in numerous studies, that might be really what we should would call success,” Sharma stated.

Photo: nonchai, Getty Images

Aethlon Medical Names Dr. Charles J. Fisher Chairman from the Board

North Park, November. 29, 2017 /PRNewswire/ — Aethlon Medical, Corporation. (Nasdaq: AEMD), a therapeutic technology company centered on unmet needs in global health insurance and biodefense, today announced the appointment of Charles (“Chuck”) J. Fisher, Junior., MD as Chairman of their Board of Company directors.

“We’re truly appreciative that Chuck has decided to expand his role inside our organization,” mentioned Aethlon founder & Chief executive officer Jim Joyce. “His leadership in evolving first-in-class therapies to promote won’ doubt lead to the pursuit to commercialize our Hemopurifier® along with other existence-saving therapeutic candidates.”

The Aethlon Hemopurifier® is really a first-in-class therapeutic device made to address existence-threatening infections. The U . s . States Fda (Food and drug administration) has designated the Hemopurifier® a “Breakthrough Device” associated with treating existence-threatening infections that aren’t cured with approved therapies.

“I’m pleased and honored the Board of Company directors have elected me Chairman from the Board. Let me use management, and also the Board of Company directors, to build up an item development strategy, resulting in regulatory approval and commercialization as quickly as you possibly can.  By doing this, we’ll consider and evaluate both organic and proper growth possibilities.  I expect to working carefully with my colleagues to attain our goals,” mentioned Dr. Fisher.

The Aethlon Board of Company directors unanimously nominated Dr. Fisher to become non-Executive Chairman and that he will stay a completely independent director under Nasdaq rules.

Dr. Fisher is really a physician researcher having a distinguished career both in academia and industry spanning over 3 decades. Being an experienced executive and entrepreneur, he brings a effective history of developing operating strategies that take products to markets, drive sales and make lucrative companies. Just before joining industry, Dr. Fisher offered as Mind from the Portion of Critical Care Medicine in the Cleveland Clinic Foundation.

Dr. Fisher’s research in sepsis, inflammation, host defense and endothelial disorder brought to his recruitment to Eli Lilly & Co., where he brought the Xigris (activated Protein C) Global Product Team and effectively registered the very first drug approved to treat sepsis. Subsequently, he was employed to Abbott Laboratories as Divisional V . P . for Global Pharmaceutical Development and research (GPRD), where, among other accomplishments, he led the registration of Humira (the very first fully humanized anti-TNF mab).

He was Chief Medical Officer and Executive V . P . of Cardiome Pharma Corp. where he brought they that invented, developed, registered vernakalant, a singular, first at school, multi-ion funnel drug for atrial fibrillation (Brinavess). He presently can serve as Executive Chairman of CytoPherx, Corporation., a clinical device company with novel IP centered on modulating acute and chronic inflammation.

Additionally, Fisher is really a multi-tour combat veteran, with extensive leadership experience of special operations. He’s offered as part of the Defense Science Research Council as well as on DARPA panels, including one centered on universal host defense.

About Aethlon Medical, Corporation.

Aethlon Medical is centered on addressing unmet needs in global health insurance and biodefense. The Aethlon Hemopurifier® is really a first-in-class therapeutic device made to address existence-threatening infections. The U . s . States Fda (Food and drug administration) has designated the Hemopurifier® a “Breakthrough Device” associated with treating existence-threatening infections that aren’t cured with approved therapies.

Together with leading government and non-government research institutes, Aethlon has validated ale the Hemopurifier® to capture an extensive-spectrum of pandemic influenza infections, bug-borne infections and deadly hemorrhagic infections.  According to its use to deal with Ebola virus, the Hemopurifier® was named a “Top 25 Invention” and among the “Eleven Most Outstanding Advances in Healthcare,” by TIME Magazine.

Aethlon can also be investigating the possibility therapeutic utilisation of the Hemopurifier® to lessen the existence of tumor-derived exosomes, which lead to immune-suppression and also the spread of metastasis in cancer patients.  Furthermore, Aethlon may be the majority who owns Exosome Sciences, Corporation. (ESI), which is centered on the invention of exosomal biomarkers to identify and monitor cancer and nerve disorders, including Alzheimer’s (AD) and Chronic Traumatic Encephalopathy (CTE).  More information are available online at world wide web.AethlonMedical.com and world wide web.ExosomeSciences.com.  You may also interact with us on Twitter, LinkedIn, Google and facebook+.

Forward Searching Statements

This pr release contains forward-searching statements inside the concept of Section 27A from the Securities Act of 1933 and Section 21E from the Securities Exchange Act of 1934 which involve risks and uncertainties. Statements that contains words for example “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” or similar expressions constitute forward-searching statements. Forward-searching statement includes statements concerning the public offering and also the satisfaction of closing conditions concerning the public offering, in addition to general economic and market factors. Such forward-searching statements are susceptible to significant risks and uncertainties and actual results may vary materially in the results anticipated within the forward-searching statements. Factors that could lead to such variations include, without limitation, the business’s capability to maintain its listing around the Nasdaq Capital Market, or other national securities exchange, that the organization or its subsidiary won’t be able to commercialize its products, the Food and drug administration won’t approve the initiation or continuation from the Company’s clinical programs or provide market clearance from the Company’s products, the business’s capability to raise investment capital if needed, the business’s capability to complete the introduction of its planned products, the business’s capability to manufacture its products either internally or through outdoors companies, the outcome of presidency rules, patent protection around the Company’s proprietary technology, ale the organization to satisfy the milestones considered in the hire DARPA, defective products exposure, uncertainty of market acceptance, competition, technological change, along with other risks. This listing of risks and uncertainties is illustrative, however is not exhaustive. Additional circumstances that may cause leads to differ materially from individuals anticipated in forward-searching statements are available underneath the caption “RisksInch within the Company’s Annual Set of Form 10-K for that year ended March 31, 2017, as well as in the business’s other filings using the Registration. Except as might be needed legally, the organization are not committed, nor will it undertake any duty, to update these details to mirror future occasions or conditions.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Corporation.
858-459-7800 extension 3300
[email protected]

Investor Relations:
John Marco
CORE IR
516 222 2560
[email protected]

View original content:http://world wide web.prnewswire.com/news-releases/aethlon-medical-names-dr-charles-j-fisher-chairman-of-the-board-300563365.html

SOURCE Aethlon Medical, Corporation.

Related Links

http://world wide web.aethlonmedical.com

Drug discount program 340B reaches center of dialogue between CMS, lawmakers and hospitals

A 25-year-old federal drug discount program is continuing to grow just too large and questionable it faces a battle for survival as federal officials and lawmakers furiously debate the program’s achieve.

This program, referred to as 340B, requires pharmaceutical companies to provide steep discounts to hospitals and clinics that provide high volumes of low-earnings patients.

The Centers for Medicare & State medicaid programs Services struck a blow towards the program this month announcing your final rule to chop Medicare payments for hospitals signed up for this program by 28 percent, or about $1.6 billion. The American Hospital Association, the Association of yankee Medical Colleges, America’s Essential Hospitals yet others sued on November. 13, quarrelling the agency lacks the legal right to slash the instalments which the rule undermines the intent Congress had when designing this program.

Advertisement

Several federal reports recently in the Medicare advisory board, along with the Government Accountability Office and also the Office of Inspector General, have evaluated 340B’s explosive growth. About 40 % from the hospitals within the U.S. now buy drugs with the program, based on the 2015 GAO report.

Richard Sorian, from the hospital lobbying group 340B Health, stated that for many small, rural hospitals the funding cut “could really function as the distinction between remaining open and shutting.Inches

Northeast Ohio’s largest safety-internet hospital, MetroHealth System in Cleveland, stated it might see an $8 million decline in Medicare reimbursements.

In attempting to explain the significance of that funding, Dr. Benjamin Li, a MetroHealth cancer surgeon, stated when the 340B program would disappear “some in our cancer patients won’t be able to possess lifesaving care.”

In comparison, individuals supporting the cut, including drugmakers, reason that this program is continuing to grow beyond its original intent because hospitals have pocketed the discounts to pad profits — to not help indigent patients.

Stephen Ubl, president from the drug industry group PhRMA, stated this program “needs fundamental reform” which the most recent rule change is just a great initial step. His group, which has deep pockets and a marketing campaign geared at pinpointing the program’s flaws, lists changes that Congress and also the Trump administration could tackle. Individuals include restricting which hospitals ought to be qualified for 340B cost breaks and ensuring needy patients benefit when hospitals buy discounted drugs.

The next day a healthcare facility groups sued, Joe Grogan, director of health programs in the White-colored House’s Office of Management and Budget, known as 340B “really messed up,Inches based on Politico, and stated the Trump administration isn’t afraid to defend myself against this program. “We aren’t wimps.” Grogan brought a White-colored House task force last summer time that suggested scaling back this program.

The hospitals — frequently the greatest employers inside a congressional district — are prepared for any fight. The American Hospital Association launched an advertisingcampaign. And countless people of Congress signed a letter defending this program. On November. 14, two House lawmakers introduced a bill that would prevent CMS from applying the suggested rule.

Under 340B, named following the portion of the Public Health Service Act that authorizes it, qualified hospitals buy drugs for a cheap price in the pharmaceutical companies after which are reimbursed for individuals purchases from Medicare. The medicine is purchased underneath the Medicare Part B program, which provides coverage for costly chemotherapy along with other treatments inside a hospital, doctor’s office and clinics.

The hospitals earn money around the spread, utilizing it to enhance the financial stability from the hospital.

In comment letters to federal officials, a variety of hospitals from St. Cloud, Minn., to Kalamazoo, Mi., stated the brand new rule would cost them thousands and thousands of dollars.

Yet, even while concerns arise round the impact from the cuts along with a legal fight plays out, Congress has increased scrutiny from the program. The Home Energy and Commerce Committee held two hearings over yesteryear couple of several weeks, analyzing how hospitals use money made on 340B drugs. A vital question for lawmakers was just how much the patients benefited.

The brand new rule, based on CMS Administrator Seema Verma, addressed that concern — although not directly.

As the actual cost of medication won’t be lower underneath the rule, Verma stated beneficiaries helps you to save an believed $320 million annually on copayments. Medicare patients typically have the effect of a portion of coinsurance on their own prescriptions. The decreased Medicare reimbursement implies that an enrollee’s coinsurance could be lower at 340B hospitals because Medicare would pay hospitals less for that drug.

In a single example the administration provided, if Medicare reimburses a participating hospital $2,000 per month for a person drug, a beneficiary would save over $100 on their own out-of-pocket share.

Dr. Peter Bach, director from the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New You are able to, agreed.

“If Medicare cuts down on the reimbursement amount, which will directly reduce exactly what the patients pay,” Bach stated. “Patients might find affordable prices.Inches

Allan Coukell, senior director for health programs in the Pew Charitable Trusts, stated the modification in how Medicare spends its money might have broader, unintended effects for that healthcare system. Patients may change providers, seeking lower copays. Or, on the other hand, hospitals may drop from the program due to lower reimbursements.

“The lengthy-term impact of these a shift is unknown,” Coukell stated, adding that certain factor is for certain: Less hospitals taking part in this program simply “transfers the 340B revenue in the provider towards the manufacturer.”

The 340B program wasn’t always so questionable. The balance, signed by Republican President George H.W. Plant in 1992, had bipartisan support.

“Everyone loved this program. That is why Congress expanded it on three separate occasions,” remembered William von Oehsen, who helped lobby for that initial law and it is a founding father of a healthcare facility group 340BHealth. Most lately, this program was expanded underneath the Affordable Care Act this year.

“There never was any worry about its size until, essentially, pharma made the decision it’d become too large and began buying a pr and lobbying campaign to reform it,” von Oehsen stated, adding, “We just don’t have the cash they’ve, and it is type of discouraging.”

KHN’s coverage of prescription medication development, costs and prices is based on the Laura and John Arnold Foundation.

Photo: Ieremy, Getty Images 

Mass. State medicaid programs program seeks capacity to negotiate drug discounts, exclude meds with little value

Money pile and medicine pills representing medical expenses

Within the absence of new federal policies to tame break-the-bank drug prices, Massachusetts’ condition State medicaid programs program wishes to road-test a concept both radical and market-driven. It wants the ability to barter reduced prices for the drugs it purchases and also to exclude drugs with limited treatment value.

“This is really a serious demonstration proposal,” stated Sara Rosenbaum, any adverse health policy expert and professor at George Washington College. “They’re not merely using [this concept] being an excuse to chop State medicaid programs. They’re attempting to move toward efficiency.”

When the Department of Health insurance and Human Services approves the Bay State’s plan, others will probably take similar action. Based on the most recent federal data, State medicaid programs paying for prescription medications elevated about 25 % in 2014 and nearly 14 % in 2015.

Advertisement

Presently, condition State medicaid programs programs are needed to pay for just about all drugs which have received Fda approval, including multiple drugs from various manufacturers used for the similar purpose as well as in exactly the same category. As a swap, manufacturers must discount individuals drugs — typically with different set number of their email list cost, specified by federal law. The concept is Medicaid’s vulnerable beneficiaries get medications they require and also the condition doesn’t go bankrupt having to pay on their behalf.

As drug prices soar, states say, individuals fractional rebates no more suffice to defray the responsibility of rising costs.

Take, for example, the hepatitis C cures released recently. The cost tags are available in tens or perhaps thousands and thousands of dollars and — despite rebates — have cost State medicaid programs billions. In turn, some states attempted to restrict access, so just the sickest patients might get the drugs. Advocates filed suit in response and won in line with the argument that such limits violated Medicaid’s statutory drug benefit.

Condition officials contend the current State medicaid programs rebate system may encourage drug cost inflation, since a collection number of a greater cost yields a larger profit. Also, the legal requirement to pay for most prescriptions leaves little wiggle room to barter a much better cost.

So, Massachusetts really wants to go another route, requesting a federal exemption referred to as a Section 1115 waiver, which is supposed to let states test methods for improving State medicaid programs. It really wants to select which drugs it covers according to most beneficiaries’ medical needs and which medicines demonstrate the greatest rates of affordability.

It states it can negotiate better prices consequently, saving public dollars while keeping patients’ use of needed therapies.

The government Centers for Medicare & State medicaid programs Services, that will ultimately approve or reject Massachusetts’ proposal, doesn’t have deadline because of its decision. A Massachusetts spokeswoman stated officials are pushing to have an answer by year’s finish.

Already, though, the pitch is popping heads.

“This is completely something lots of other states are searching very carefully at,” stated Matt Salo, executive director from the National Association of State medicaid programs Company directors.

When the request qualifies, agreed Jane Horvath, a senior policy fellow in the National Academy for Condition Health Policy, other states would follow “in about 5 minutes.Inches

Critics worry this transformation might make it tougher for low-earnings individuals to get needed medications, without always supplying them an alternate. Previously decade, though, it is commonplace for those who have commercial insurance to possess limited drug choices — meaning only individuals medicines for auction on a plan’s formulary are covered.

The Pharmaceutical Research and Manufacturers of the usa (PhRMA), the drug industry’s trade group, has lodged its displeasure, saying this could limit consumer access and it is unnecessary on the top from the rebates State medicaid programs programs receive.

“The pharmaceutical industry includes a status to be litigious. This is an issue on their behalf,Inches stated Andy Schneider, a State medicaid programs expert at Georgetown College, who labored at CMS underneath the Federal government. If CMS approves the waiver, analysts stated, the may likely sue, though PhRMA wouldn’t discuss potential law suit.

But federal approval isn’t any sure factor.

On a single hands, the Trump administration has encouraged states to check changes that will run State medicaid programs a lot more like a personal insurance policy. Using that frame, Massachusetts’ approach appears may well fit. Though a proper strategy is not released, President Jesse Trump has said his administration promises to bring drug prices “way lower.”

However, analysts stated, CMS’ decision-making regarding waivers has shown unpredictable. The company declined to comment beyond confirming it had been reviewing Massachusetts’ request.

It’s obvious why states have an interest. Typically, between 25 and 30 % of condition budgets visit State medicaid programs, and program company directors across the nation identify rising drug costs as a significant cause of spending increases, based on a current survey by the Kaiser Family Foundation. (Kaiser Health News is definitely an editorially independent program from the foundation.)

In Massachusetts, State medicaid programs makes up about about 40 % from the state’s budget. Prescription-drug spending has previously seven years greater than bending — from about $917 million this year to around $1.94 billion this past year, based on figures supplied by the condition health department.When the waiver qualifies, the state’s State medicaid programs program would cover a minumum of one medication per therapeutic class — that’s, per specific medical need.

Additionally, it might have an appeals process that people obtain off-formulary drugs covered, if they’re medically necessary.

Number crunchers say it’s difficult to estimate what this could save. This will depend about how the condition negotiates, how industry responds and just what this program covers. The possibility outcome is significant, though.

“You’d need to be foolish to not think about this,Inches stated Ameet Sarpatwari, an epidemiologist and lawyer at Harvard School Of Medicine, who studies drug prices and related legislation.

But consumer groups be worried about Medicaid’s low-earnings beneficiaries, even while they acknowledge that rising drug pricing is unsupportable for condition budgets.

“The State medicaid programs population differs from the commercially insured — they’re more susceptible and also have a much more happening within their lives, and tend to be poorer. So that they have less sources to get the help and prescription medications they require,Inches stated Suzanne Curry, affiliate director of policy and government relations at Healthcare For Those, a Massachusetts-based advocacy group.

Although Massachusetts, a condition having a lengthy good reputation for innovation, has dedicated to ensuring patients get needed medicine, “you need to ask what’s going to real-world implementation appears like,Inches stated Benjamin Sommers, an affiliate professor of health policy and financial aspects at Harvard’s public health school. Appeals processes, he noted, could be burdensome or restrictive.

As well as if Massachusetts receives federal approval, still it couldn’t challenge the price of certain costly drugs which are the only real offering within their therapeutic class. For example, Spinraza, which treats the rare but debilitating disease of spine muscular atrophy, includes a cost tag of $750,000 to have an initial year of treatment. Without any therapeutic equivalent, it might still need to be covered.

But states are eager to break the rules in new ways and nonetheless they can. “We have experienced previously year … drugs which have almost bankrupted condition budgets,” Sarpatwari stated. “There will be numerous other states that’ll be thinking about after this lead.”

KHN’s coverage of prescription medication development, costs and prices is based on the Laura and John Arnold Foundation.

Kaiser Health News, a nonprofit health newsroom whose tales come in news outlets nationwide, is definitely an editorially independent area of the Kaiser Family Foundation.

Photo: gerenme, Getty Images